DEXA scanning for osteoporosis in patients on aromatase inhbitors – pro

Breast cancer patients are at an increased risk of osteoporosis due to age, cancer, chemotherapy, and aromatase inhibitor therapy.  The latter, by depriving the bone of estrogenic stimulation both promotes and accelerates osteoporosis. Because of this, imaging to detect and follow this condition as well as bisphosphonates used to treat osteoporosis,  are standard treatment along with the aromatase inhibitor. Guidelines recommend a baseline DEXA

Read more
Xgeva off-label and for prostate cancer – pro

Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Its indication is not very different from Zometa: Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. For

Read more